WO2004026824A1 - Process for preparing intermediates - Google Patents

Process for preparing intermediates Download PDF

Info

Publication number
WO2004026824A1
WO2004026824A1 PCT/EP2003/010416 EP0310416W WO2004026824A1 WO 2004026824 A1 WO2004026824 A1 WO 2004026824A1 EP 0310416 W EP0310416 W EP 0310416W WO 2004026824 A1 WO2004026824 A1 WO 2004026824A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
hydrogen
formula
alkyl
contacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/010416
Other languages
English (en)
French (fr)
Inventor
Prasad Koteswara Kapa
Xinglong Jiang
Eric M. Loeser
Joel Slade
Mahavir Prashad
George Tien-San Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/527,628 priority Critical patent/US7589216B2/en
Priority to AU2003273404A priority patent/AU2003273404B2/en
Priority to JP2004537129A priority patent/JP2006503053A/ja
Priority to DE60325390T priority patent/DE60325390D1/de
Priority to NZ538833A priority patent/NZ538833A/en
Priority to EP03755559A priority patent/EP1542968B1/en
Priority to HK05111407.9A priority patent/HK1079513B/en
Priority to CA002499426A priority patent/CA2499426A1/en
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Priority to MXPA05003089A priority patent/MXPA05003089A/es
Priority to DK03755559T priority patent/DK1542968T3/da
Priority to BR0314592-1A priority patent/BR0314592A/pt
Publication of WO2004026824A1 publication Critical patent/WO2004026824A1/en
Anticipated expiration legal-status Critical
Priority to NO20051867A priority patent/NO20051867L/no
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention is directed to a process for preparing intermediates that are useful to prepare certain antibacterial ⁇ /-formyl hydroxylamine compounds.
  • Peptide deformylase is a metallopeptidase found in prokaryotic organisms such as bacteria. Protein synthesis in prokaryotic organisms begins with ⁇ /-formyl methionine (fMet). After initiation of protein synthesis, the formyl group is removed by the enzyme peptide deformylase (PDF); this activity is essential for maturation of proteins. It has been shown that PDF is required for bacterial growth (see Chang et al., J. Bacteriol., Vol. 171 , pp. 4071- 4072 (1989); Meinnel et al., J. Bacteriol., Vol. 176, No. 23, pp. 7387-7390 (1994); Mazel et al., EMBO J., Vol. 13, No. 4, pp. 914-923 (1994)). Since protein synthesis in eukaryotic organisms does not depend on fMet for initiation, agents that will inhibit PDF are attractive candidates for development of new anti-microbial and anti-bacterial drugs.
  • PDF
  • the present invention is directed to a novel process for preparing certain intermediates which are useful to prepare certain ⁇ /-formyl hydroxylamine compounds which are useful for inhibiting bacteria.
  • the present invention is directed to a process for preparing a compound of the formula (VIII)
  • Y is a hydroxy protecting group
  • each of R 2 , R 3 , R 4 and R 5 is independently hydrogen or an aliphatic group, or (R 2 and R 3 ) and/or (R 4 and R 5 ) collectively form a C 4 . 7 cycloalkyl;
  • R is alkyl
  • G is -OH or -O ⁇ M ® , wherein M is a metal or an ammonium moiety; Ri is aryl or heteroaryl;
  • X' is halo
  • R' is alkyl or aryl; and n is 0 to 3, provided that when n is 0, X is -CH 2 -.
  • Step F When the desired product is an ⁇ /-oxide of an aromatic moiety having a nitrogen heteroatom, e.g., when R is formula (X), (Xla) or (Xb), typically a pyridine derivative, it is necessary to perform an additional step after Step E, i.e., to oxidize the N of the aromatic ring (Step F). Therefore, the present invention includes Step F which comprises contacting the compound of formula (VIII), wherein R ⁇ is heteroaryl having an N heteroatom, with an oxidizing agent to form the corresponding ⁇ /-oxide derivative.
  • Step F comprises contacting the compound of formula (VIII), wherein R ⁇ is heteroaryl having an N heteroatom, with an oxidizing agent to form the corresponding ⁇ /-oxide derivative.
  • the present invention is directed to each of the steps individually, and to any two or more sequential steps.
  • the present invention provides a process for preparing intermediates useful in the preparation of a ⁇ /-[1-oxo-2-alkyl-3-( ⁇ /-hydroxyformamido)-propyl]- (carbonylamino-aryl or -heteroaryl)-azacyclo 4-7 alkane or thiazacyclo 4-7 alkane, e.g., a compound of formula (IX)
  • R ⁇ R 2> R 3 , R 4 ,R5, X and n are as defined above.
  • the hydroxy protecting group is removed using conventional hydrogenolysis techniques known in the art, e.g., by contacting the compound of formula (VIII) with a palladium catalyst, such as Pd/BaSO 4 .
  • the Ri moiety can be a heteroaryl, e.g., an azacyclo -7 alkane, a thiazacyclo 4-7 alkane or an imidazacyclo 4-7 alkane.
  • Specific examples of Ri moieties in the compounds disclosed herein are heteroaryls of formula (X)
  • each of R 6 , R 7 , Re and R 9 independently, is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, acyl, acyloxy, SCN, halogen, cyano, nitro, thioalkoxy, phenyl, heteroalkylaryl, alkylsulfonyl or formyl.
  • Ri moiety is a heteroaryl of formula (Xla)
  • R 6 , R 7 , R 8 and R 9 are as defined above for formula (X), e.g., wherein a) R 6 is nitro, alkyl, substituted alkyl, phenyl, hydroxy, formyl, heteroalkylaryl, alkoxy, acyl or acyloxy; preferably alkyl, especially C 1-7 alkyl; hydroxyl; or alkoxy, especially a C 1- alkoxy; and R 7 , R 8 and R 9 are hydrogen; or b) R 6 , Re and R 9 are hydrogen; and
  • R 7 is alkyl, substituted alkyl, phenyl, halogen, alkoxy or cyano, preferably alkyl, especially C 1-7 alkyl; substituted alkyl, especially substituted C 1-7 alkyl, such as -CF 3 ; or alkoxy, especially C 1-7 alkoxy; or c) R 6 , R 7 and R 9 are hydrogen; and
  • R 8 is alkyl, substituted alkyl, halogen, nitro, cyano, thioalkoxy, acyloxy, phenyl, alkylsulfonyl or carboxyalkyl, preferably alkyl, especially d -7 alkyl; substituted alkyl, especially -CF 3 ; halogen such as chloro, bromo or fluoro; or carboxyalkyl; or d) R 6 , R 7 and R 8 are hydrogen; and R 9 is alkyl, halogen or hydroxy; or e) R 7 and R 9 are hydrogen; and each of R 6 and R 8 , independently, is halogen, alkyl, substituted alkyl, phenyl or cyano; or f) Each of R 7 and R 9 is alkyl or substituted alkyl; and R 6 and R 8 are hydrogen; or g) R 6 and R 9 are hydrogen;
  • R 7 is alkyl or substituted alkyl; and R 8 is nitro; or h) R 8 and R 9 are hydrogen; R 6 is cyano; and R 7 is alkoxy; or i) R 7 and R 8 are hydrogen; and
  • R 6 is alkyl, substituted alkyl, alkoxy or SCN; and R 9 is alkyl or substituted alkyl; or j) R 6 and R 7 are hydrogen; R 8 is nitro or halogen; and R 9 is alkyl or substituted alkyl; or k) R 6 , R 7 , R 8 and R 9 are hydrogen; or
  • R 6 and R 7 together with the carbon atoms to which they are attached form a phenyl group, preferably substituted with hydroxy; and R 8 and R 9 are hydrogen; or m) R 6 and R 7 are hydrogen; and
  • R 8 and R 9 together with the carbon atoms to which they are attached form a phenyl group; or n) n is 0; or o) n is 0; each of R 6 , R , R 8 and R 9 , independently, is hydrogen, alkyl or halogen; and more particularly, R 6 , R 7 , R 8 and R 9 are hydrogen; or p) n is 0;
  • R 6 , Re and R 9 are hydrogen; and R 7 is alkyl; or q) n is 0;
  • R 6 , R and R 9 are hydrogen; and R 8 is alkyl or halogen.
  • R is of formula (Xb)
  • Re, R7, Re and R 9 are as defined above for formula (X); in particular, R 7 and R 8 together with the carbon atoms to which they are attached form a phenyl group; and R 6 and R 9 are hydrogen.
  • the R is of formula (XI)
  • each of R 6 , R 7 , R 8 and R 9 independently is hydrogen, alkyl, substituted alkyl, phenyl, halogen, hydroxy or alkoxy, e.g., wherein a) R 6 and R 8 are hydrogen;
  • R 9 is hydrogen or alkyl
  • R 7 is alkyl, substituted alkyl or phenyl; or b) R 6 , R and R 9 are hydrogen; and
  • R 8 is halogen, alkyl or substituted alkyl; or c) R 7 , R 8 and R 9 are hydrogen; and R 6 is hydroxy.
  • heteroaryl is of the formula (Xla)
  • R 6 , R 7 , R 8 and R 9 are as defined above for formula (XI), in particular where R 6 , R 7 , and R 9 are hydrogen and R 8 is fluoro.
  • R T is an unsubstituted phenyl or the phenyl is substituted with alkoxy, e.g., methoxy; or aryloxy, e.g., phenoxy.
  • the R is of formula (XII)
  • each of R 10 and Rn independently, is hydrogen or halogen.
  • R 10 and Rn are both either hydrogen or both halogen.
  • M is a metal, typically a mono- or di-valent metal or an ammonium moiety.
  • Typical metals include Mg, Ca, Na, K, Li and the like.
  • the ammonium moiety is of the formula
  • R" is hydrogen, alkyl, substituted alkyl, aryl or substituted aryl.
  • ammonium moiety can be racemic or chiral.
  • An example of an ammonium moiety is f?- ⁇ -methylbenzylammonium.
  • R" groups include hydrogen, methyl, ethyl, propyl, butyl, phenyl, benzyl, methylbenzyl and the like.
  • cycloalkane or "cycloalkyl” contains from 3- to 7-ring carbon atoms, and is, e.g., cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • azacyclo 4-7 alkane contains 1-ring heteroatom which is a nitrogen. It contains from 4-7, and especially 4- or 5-ring atoms including the heteroatom.
  • thiazacyclo 4-7 alkane contains 2-ring heteroatoms, nitrogen and sulfur. It contains from 4-7, and especially 5-ring atoms including the heteroatoms.
  • imidazacyclo ⁇ alkane contains 2-ring heteroatoms which are both nitrogen. It contains from 4-7, and especially 5-ring atoms including the heteroatoms.
  • aliphatic group refers to saturated or unsaturated aliphatic groups, such as alkyl, alkenyl or alkynyl, cycloalkyl or substituted alkyl including straight-chain, branched- chain and cyclic groups having from 1-10 carbons atoms.
  • alkyl or “alk” whenever it occurs, is a saturated aliphatic group or cycloalkyl, more preferably C 1-7 alkyl, particularly C 1-4 alkyl.
  • alkyl or “alk” include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, f-butyl, n-pentyl, neopentyl, n-hexyl or n-heptyl, cyclopropyl and especially n-butyl.
  • substituted alkyl refers to an alkyl group that is substituted with one or more substituents preferably 1-3 substituents including, but not limited to, substituents, such as halogen, lower alkoxy, hydroxy, mercapto, carboxy, cycloalkyl, aryl, heteroaryl and the like.
  • substituents such as halogen, lower alkoxy, hydroxy, mercapto, carboxy, cycloalkyl, aryl, heteroaryl and the like.
  • substituted alkyl groups include, but are not limited to, -CF 3 , -CF 2 -CF 3 , hydroxymethyl, 1- or 2-hydroxyethyl, methoxy methyl, 1- or 2-ethoxyethyl, carboxymethyl, 1- or 2-carboxyethyl and the like.
  • aryl refers to an aromatic carbocyclic group of 6-14 carbon atoms having a single ring including, but not limited to, groups, such as phenyl; or multiple condensed rings including, but not limited to, groups, such as naphthyl or anthryl; and is especially phenyl.
  • heteroaryl refers to a 4- to 7-membered, monocyclic aromatic heterocycle or a bicycle that is composed of a 4- to 7-membered, monocyclic aromatic heterocycle and a fused-on benzene ring.
  • the heteroaryl has at least one hetero atom, preferably one or two heteroatoms including, but not limited to, heteroatoms, such as N, O and S, within the ring.
  • a preferred heteroaryl group is pyridinyl, pyrimidinyl or benzdioxolanyl.
  • the aryl or heteroaryl may be unsubstituted or substituted by one or more substituents including, but not limited to, C 1-7 alkyl, particularly C 1-4 alkyl, such as methyl, hydroxy, alkoxy, acyl, acyloxy, SCN, halogen, cyano, nitro, thioalkoxy, phenyl, heteroalkylaryl, alkylsulfonyl and formyl.
  • substituents including, but not limited to, C 1-7 alkyl, particularly C 1-4 alkyl, such as methyl, hydroxy, alkoxy, acyl, acyloxy, SCN, halogen, cyano, nitro, thioalkoxy, phenyl, heteroalkylaryl, alkylsulfonyl and formyl.
  • carbonylamine refers to a -NHC(O)- group wherein the amino portion of the group is linked to the aryl/heteroaryl and the carbonyl portion of the group is linked to the azacyclo 4 . 7 alkane, thiazacyclo 4-7 alkane or imidazacyclo 4-7 alkane.
  • heteroalkyl refers to saturated or unsaturated C 1-10 alkyl as defined above, and especially which contain one or more heteroatoms, as part of the main, branched or cyclic chains in the group.
  • Heteroatoms may independently be selected from the group consisting of -NR-, where R is hydrogen or alkyl, -S-, -O- and -P-; preferably -NR-, where R is hydrogen or alkyl; and/or -0-. Heteroalkyl groups may be attached to the remainder of the molecule either at a heteroatom (if a valence is available) or at a carbon atom.
  • heteroalkyl groups include, but are not limited to, groups, such as -O- CH 3 , -CH 2 -0-CH 3 , -CH 2 -CH 2 -0-CH 3 , -S-CH 2 -CH 2 -CH 3 , -CH 2 -CH(CH 3 )-S-CH 3 and -CH 2 -CH 2 - NH-CH 2 -CH 2 -.
  • the heteroalkyl group may be unsubstituted or substituted with one or more substituents, preferably 1-3 substituents including, but not limited to, alkyl, halogen, alkoxy, hydroxyl, mercapto, carboxy and especially phenyl.
  • the heteroatom(s) as well as the carbon atoms of the group may be substituted.
  • the heteroatom(s) may also be in oxidized form.
  • alkoxy refers to a C h alky! linked to an oxygen atom, or preferably C 1-7 alkoxy, more preferably C 1-4 alkoxy.
  • alkoxy groups include, but are not limited to, groups such as methoxy, ethoxy, n-butoxy, terf-butoxy and allyloxy.
  • acyl refers to the group -(O)CR, where R is alkyl, especially C 1-7 alkyl, such as methyl.
  • R is alkyl, especially C 1-7 alkyl, such as methyl.
  • acyl groups include, but are not limited to, acetyl, propanoyl and butanoyl.
  • acyloxy refers to the group -OC(0)R, wherein R is hydrogen, alkyl, especially C 1-7 alkyl, such as methyl or ethyl, or phenyl or substituted alkyl as defined above.
  • alkoxycarbonyl refers to the group -COOR, wherein R is alkyl, especially C 1-7 alkyl, such as methyl or ethyl.
  • halogen refers to chlorine, bromine, fluorine, iodine and is especially fluorine.
  • thioalkoxy means a group -SR, where R is an alkyl as defined above, e.g., methylthio, ethylthio, propylthio, butylthio and the like.
  • heteroalkylaryl means a heteroalkyl group, e.g., -O-CH 2 - substituted with an aryl group, especially phenyl.
  • the phenyl group itself may also be substituted with one or more substituents, such as halogen, especially fluoro and chloro; and alkoxy, such as methoxy.
  • alkylsulfonyl means a group -S0 2 R, wherein R is alkyl, especially C 1-7 alkyl, such as methyl sulfonyl.
  • Protecting group refers to a chemical group that exhibits the following characteristics: 1 ) reacts selectively with the desired functionality in good yield to give a protected substrate that is stable to the projected reactions for which protection is desired; 2) is selectively removable from the protected substrate to yield the desired functionality; and 3) is removable in good yield by reagents compatible with the other functional group(s) present or generated in such projected reactions.
  • suitable protecting groups may be found in Greene et al., "Protective Groups in Organic Synthesis", 3 rd Ed., John Wiley & Sons, Inc., NY (1999).
  • Preferred hydroxy protecting groups include benzyl, Fmoc, TBDMS, photolabile protecting groups, such as Nvom, Mom and Mem.
  • Other preferred protecting groups include NPEOC and NPEOM.
  • the compounds disclosed herein may exist in the form of optical isomers, racemates or diastereoisomers.
  • the carbon atom to which the R 4 and R 5 groups are bonded is a chiral center and such compounds can exist in the R, S or racemic forms.
  • the process of the invention prepares the R optically pure form.
  • optically pure is meant that the enantiomeric purity is greater than 50%, preferably greater than 80%, more preferably greater than 90%, and most preferably greater than 95%.
  • the optically pure R isomer of compound (I) can be used, in which case all subsequent compounds in the synthesis will remain in the R optically pure form, with respect to the same chiral carbon atom. If an optically pure compound is used as the starting material, purification from the undesired diastereomer can be avoided at later steps.
  • Such R form of compound (I) is represented below: wherein R 2 , R 3 , R 4 and R 5 are as defined above.
  • the optically pure form of compound (I) is novel provided that when either R 4 or R 5 is hydrogen, the other substituent, i.e., R 4 or R 5 , is not hydrogen or methyl.
  • R 5 is hydrogen andR 4 is C 2- ⁇ 0 alkyl, in a more particular embodiment C 2-7 alkyl, and in a even more particular embodiment C 4 alkyl.
  • an optically pure compound of formula (I) t R 2 , R 3 , and R 5 are hydrogen and R 4 is alkyl; such a compound has the structure (la):
  • R 2 , R 3 and R 5 are hydrogen and R 4 is n-butyl; such compound has the structure (lc):
  • optically pure compound of formula (I) More particular examples of the optically pure compound of formula (I) are as follows:
  • the racemate form of compound (I) can be used and then the R form can be resolved at a later step and the R form used for subsequent steps.
  • the compound formed after opening the ⁇ -lactam ring i.e., compound (VII), the product of Step D, can be resolved into its RS and SS diastereomers and only the RS diastereomer used for subsequent steps.
  • the RS diastereomer of compound (VII) is depicted below:
  • R 2 , R 3 , R 4 R 5 Y, X, R and n are as defined above, provided that R 4 and R 5 are different.
  • the diastereoisomers are resolved using standard techniques known in the art, for example, using silica gel column chromatography and an ethyl acetate/hexane solvent
  • R T is a heteroaryl of formula (Ha), wherein R 6 , R 7 and R 9 are hydrogen and R 8 is methyl or trifluoromethyl; or R 6 , R 7 and R 8 are hydrogen and R 9 is fluoro; or R 6 , R 8 and R 9 are hydrogen and R 7 is ethyl or methoxy; or R 7 , R 8 and R 9 are hydrogen and R 6 is hydroxy; or R 7 and R 8 are hydrogen, R 6 is methoxy and R 9 is methyl; or R ⁇ is a heteroaryl of formula (Ilia), wherein R 6 , R 7 and R 9 are hydrogen and R 8 is fluoro or trifluoromethyl; or R 6 , R 8 and R 9 are hydrogen and R 7 is ethyl; preferably Ri is a heteroaryl of formula (Ma), wherein R 6 , R 8 and R 9 are hydrogen and R 7 is ethyl or a heteroaryl of formula (Ilia), wherein R 6 , R 7 and R
  • X is -CH 2 -, -CH(OH)-, -CH(OR)-, -CF 2 - or -CH(F)-, preferably X is -CH 2 -;
  • R 4 is alkyl, preferably C 1-7 alkyl, such as n-butyl;
  • n 1.
  • Temperature and pressure are not known to be critical for carrying out any of the steps of the invention, i.e., Steps A through E.
  • a temperature of about -10°C to about 150°C, preferably about 0°C to about 80°C is typically employed.
  • atmospheric pressure is used for convenience; however, variations to atmospheric pressure are not known to be detrimental.
  • Oxygen is not known to be detrimental to the process, therefore for convenience the various steps can be performed under ambient air, although an inert atmosphere, such as nitrogen or argon, can be used if desired.
  • an inert atmosphere such as nitrogen or argon
  • equimolar amounts of reactants are typically used; however molar ratios can vary from about 1 to 2 equivalents, relative to the other reactant.
  • the pH for the various steps is typically about 2 to about 12.
  • the solvent used for the various steps are typically organic solvents, although in some situations aqueous/organic solvents can be used.
  • suitable solvents include dioxane; mtehylene chloride; dichloromethane; toluene, acetone; methyl ethyl ketone; THF; isopropyl acetate; DMF; alcohols, especially higher branched alcohols, such as f-butanol; and the like.
  • a typical temperature is about 0°C to about 50°C, preferably about 5°C to about 35°C; and a typical reaction time is about 1 hour to about 10 hours, preferably about 2 hours to about 5 hours.
  • a pH of about 2 to about 7, preferably about 3 to about 5, more preferably about 4, is typically employed.
  • the carboxy-activating agent can be for example, DCC, CDMT, EDCI and the like.
  • the amount of carboxy-activating agent employed is typically about 0.5 to about 2 molar equivalents relative to compound (I).
  • the solvent is water or a mixture of water and one or more organic solvents, such as THF, dioxane, alcohols, such as methanol, ethanol and the like. Specific examples of solvents include THF/water and water.
  • an ammonium salt of compound (I) is used in the process, the salt will be dissolved in water containing at least a molar equivalent amount of base, such as alkaline metal hydroxide, such as NaOH and KOH; the base is added to liberate the free amine which is extracted into the organic phase, the aqueous phase is used for the coupling reaction.
  • base such as alkaline metal hydroxide, such as NaOH and KOH
  • a typical temperature is about -20°C to about 25°C, more typically about -5°C to about 5°C; and a typical reaction time is about 1 hour to about 2 hours, more typically about 2 hours to about 5 hours.
  • an alcoholic solvent should not be used.
  • X' is preferably chloro and R' is preferably lower alkyl or phenyl, with CH 3 S0 2 CI and tosyl chloride being most typical.
  • the pH for Step B is basic and is typically about 9 to about 10.
  • the base used for Step B can be any conventional base known in the art that will activate the hydroxy group of compound (III), and such base will be used in a hydroxyl-activating amount which is at least about 1 molar equivalent relative to compound (III).
  • the base can also act as solvent in which case it will be present in a solvating amount which is in excess of the above amount.
  • bases that can be employed include pyridine; DMAP; a trialkylamine, e.g., trimethylamine; resin-bound bases; Hunig bases; and the like.
  • a particular solvent is pyridine, THF or EtOAc.
  • a typical temperature is about 20°C to about 150°C, more typically about 40°C to about 80°C; and a typical reaction time is about 1 hour to about 20 hours, more typically about 2 hours to about 4 hours.
  • the pH for Step C is basic, typically, about 8 to about 12.
  • suitable bases include inorganic or organic bases, such as potassium carbonate; lithium carbonate; sodium carbonate; lithium bicarbonate; sodium bicarbonate; alkyl lithium, e.g., butyl lithium; and the like.
  • the amount of base employed is a de-protonating amount which is typically in molar excess to the amount of compound (IV), e.g., about 1-5 equivalents relative to compound (IV).
  • a phase transfer catalyst such as trialkylarylammonium salt or a tetraalkylammonium salt, e.g., tetrabutylammonium chloride or tetrabutylammonium bromide.
  • a phase transfer catalyst such as trialkylarylammonium salt or a tetraalkylammonium salt, e.g., tetrabutylammonium chloride or tetrabutylammonium bromide.
  • the examples of solvents are ketones, such as acetone or methylethylketone.
  • a typical temperature is about 30°C to about 150°C, more typically about 60°C to about 80°C; and a typical reaction time is about 3 hours to about 20 hours, more typically about 5 hours to about 10 hours.
  • the pH for Step D is typically about 5 to about 11.
  • the activator for Step D is a compound which protonates the ⁇ -lactam keto oxygen; such activators include, e.g., mild (weak) organic acids, such as branched or unbranched carboxylic acids, e.g., 2-ethylhexanoic acid, acetic acid, isobutryic acid and the like.
  • an activator is not needed; examples ofd aqueous alcoholic solvents include MeOH H 2 0, EtOH H 2 0 and the like. If an activator is used a typical solvent is THF, dioxane or dimethoxyethane. If an activator is used it is used in an protonating amount which is typically about 0.1 molar equivalents to about 2 molar equivalents relative to compound (V).
  • a typical temperature is about -30°C to about 50°C, more typically about 0°C to about 25°C; and a typical reaction time is about 10 minutes to about 5 hours, more typically about 20 minutes to about 1 hour.
  • the pH for Step E is not critical and can vary considerably.
  • the solvent should not be an alcoholic solvent.
  • the formylating agent can be, for example, HC0 2 H/Ac 2 O, trifluoroethylformate, and the like, and is present in a formylating amount which is typically about 1 molar equivalent to about 2 molar equivalents relative to compound (VII).
  • a typical solvent is EtOAc, isopropylacetate, f-butylacetate or THF.
  • a typical temperature is about 10°C to about 35°C, more typically about 20°C to about 22°C; and a typical reaction time is about 60 minutes to about 18 hours, more typically about 4 hours to about 8 hours.
  • the pH for Step F is typically about 4 to about 8.
  • the solvent for Step F is typically an organic solvent, i.e., ethyl acetate, iso-propyl acetate, methylene chloride, and the like.
  • the oxidizing agent can be a conventional agent known in the art, e.g., as disclosed in March, "Advanced Organic Chemistry", Chapter 19, 5 th edition, Wiley Interscience, NY, incorporated herein by reference.
  • Typical oxidizing agents include urea/hydrogen peroxide with phthalic anhydride; magnesium monoperoxyphthalate (MMPP); MCPBA, Oxone (available from Aldrich), and the like.
  • MMPP magnesium monoperoxyphthalate
  • MCPBA Oxone (available from Aldrich), and the like.
  • the compounds are known or may be prepared analogously to methods known in the art or as disclosed in the examples hereinafter.
  • CDMT chlorodimethoxy triazine
  • EDCI 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride
  • Mem methoxy ethoxy methyl ether
  • NPEOC 4-nitrophenethyloxycarbonyl
  • NPEOM 4-nitrophenethyloxy- methyloxycarbonyl
  • THF tetrahydrofuran
  • a flask was charged with 2.80 g (19.2 mmol) of A1, 80 mL of THF, 20 mL of water, and 4.73 g (38.4 mmol) of A2. The resulting solution was stirred at RT and the pH of the solution was adjusted to 4.2-4.5 with 2N HCI acid solution.
  • the organic solvent was concentrated and diluted with 400 mL of ethyl acetate and washed with 100 mL of 1N HCI acid, 100 mL of saturated sodium bicarbonate solution, 100 mL of brine and dried over MgSO 4 .
  • the concentration of organic solvent under reduced pressure afforded 7.96 g of A5 (liquid, 90% yield).
  • the lactam ring can also be opened by a base, such as lithium hydroxide. As depicted below, the opening ring product was obtained in 91.5% yield with high purity after work-up.
  • any other ammonium salts of (2f? -2-(hydroxymethyl)hexanoic acid can be used after removing the amine component as described in Example 3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Press Drives And Press Lines (AREA)
PCT/EP2003/010416 2002-09-19 2003-09-18 Process for preparing intermediates Ceased WO2004026824A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
HK05111407.9A HK1079513B (en) 2002-09-19 2003-09-18 Process for preparing intermediates
JP2004537129A JP2006503053A (ja) 2002-09-19 2003-09-18 中間体の製造法
DE60325390T DE60325390D1 (de) 2002-09-19 2003-09-18 Verfahren zur herstellung von zwischenprodukten
NZ538833A NZ538833A (en) 2002-09-19 2003-09-18 Process for preparing intermediates
EP03755559A EP1542968B1 (en) 2002-09-19 2003-09-18 Process for preparing intermediates
CA002499426A CA2499426A1 (en) 2002-09-19 2003-09-18 Process for preparing n-hydroxylamine compounds
MXPA05003089A MXPA05003089A (es) 2002-09-19 2003-09-18 Proceso para preparar intermediarios.
US10/527,628 US7589216B2 (en) 2002-09-19 2003-09-18 Process for preparing N-hydroxyformamido-propyl pyrrolidin compounds and intermediates
AU2003273404A AU2003273404B2 (en) 2002-09-19 2003-09-18 Process for preparing intermediates
DK03755559T DK1542968T3 (da) 2002-09-19 2003-09-18 Fremgangsmåde til fremstilling af mellemforbindelser
BR0314592-1A BR0314592A (pt) 2002-09-19 2003-09-18 Processo para preparação de intermediários
NO20051867A NO20051867L (no) 2002-09-19 2005-04-18 Fremgangsmate for fremstilling av intermediater

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41192002P 2002-09-19 2002-09-19
US60/411,920 2002-09-19
US48024203P 2003-06-20 2003-06-20
US60/480,242 2003-06-20

Publications (1)

Publication Number Publication Date
WO2004026824A1 true WO2004026824A1 (en) 2004-04-01

Family

ID=32033579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/010416 Ceased WO2004026824A1 (en) 2002-09-19 2003-09-18 Process for preparing intermediates

Country Status (20)

Country Link
US (1) US7589216B2 (https=)
EP (1) EP1542968B1 (https=)
JP (1) JP2006503053A (https=)
KR (1) KR20050057429A (https=)
CN (1) CN100439334C (https=)
AT (1) ATE417826T1 (https=)
AU (1) AU2003273404B2 (https=)
BR (1) BR0314592A (https=)
CA (1) CA2499426A1 (https=)
DE (1) DE60325390D1 (https=)
DK (1) DK1542968T3 (https=)
EC (1) ECSP055692A (https=)
ES (1) ES2321504T3 (https=)
MX (1) MXPA05003089A (https=)
NO (1) NO20051867L (https=)
NZ (1) NZ538833A (https=)
PL (1) PL374961A1 (https=)
PT (1) PT1542968E (https=)
RU (1) RU2374227C2 (https=)
WO (1) WO2004026824A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589216B2 (en) 2002-09-19 2009-09-15 Novartis Ag Process for preparing N-hydroxyformamido-propyl pyrrolidin compounds and intermediates

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283589T3 (es) 2001-06-15 2007-11-01 Vicuron Pharmaceuticals, Inc. Compuestos biciclicos de pirrolidina.
JP2006519786A (ja) 2003-02-21 2006-08-31 ノバルティス アクチエンゲゼルシャフト N−ホルミルヒドロキシルアミン化合物を得るための中間体作成に関する化学的方法
GT200600196A (es) * 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina
CN101434570B (zh) * 2007-11-16 2011-02-02 上海医药工业研究院 吡咯烷衍生物及其制备方法和应用
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115417A (en) * 1975-10-16 1978-09-19 Hoffmann-La Roche Inc. Asymmetric hydrogenation catalyzed by rhodium complexes of chiral tertiary phosphines
US4384139A (en) * 1980-08-20 1983-05-17 Kanegafuchi Chemical Industry Company, Limited Process for preparation of an optically active β-mercaptoalkanoic acid
EP0354529A2 (en) * 1988-08-09 1990-02-14 Genencor International, Inc. Chiral hydroxycarboxylic acids from prochiral diols
WO1999039704A1 (en) * 1998-02-07 1999-08-12 British Biotech Pharmaceuticals Limited Antibacterial agents
WO2002070541A2 (en) * 2001-03-01 2002-09-12 Smith Kline Beecham Corporation Peptide deformylase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU384814A1 (ru) * 1970-12-25 1973-05-29 Всесоюзный научно исследовательский институт тетических , натуральных душистых веществ СПОСОБ ПОЛУЧЕНИЯ р-МЕТИЛЗАМЕЩЕННЫХ со-ОКСИКАРБОНОВЫХ КИСЛОТ
JPS5377010A (en) * 1976-12-16 1978-07-08 Mitsui Toatsu Chem Inc Preparation of hydroxypivalic acid
JPS5953839B2 (ja) * 1980-10-06 1984-12-27 鐘淵化学工業株式会社 (−)−α−ヒドロキシメチル酪酸の製造方法
JPH01149751A (ja) * 1987-12-08 1989-06-12 Agency Of Ind Science & Technol 2−n−ヘキシル−3−ヒドロキシ−n−デカン酸及びそのエステル
JPH0592948A (ja) * 1991-02-06 1993-04-16 Yoshitomi Pharmaceut Ind Ltd プロピオン酸アミド誘導体およびその医薬用途
US6977141B2 (en) * 1998-02-10 2005-12-20 Vicuron Pharmaceuticals Inc. Direct adsorption scintillation assay for measuring enzyme activity and assaying biochemical processes
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
ES2283589T3 (es) * 2001-06-15 2007-11-01 Vicuron Pharmaceuticals, Inc. Compuestos biciclicos de pirrolidina.
JP2006052138A (ja) * 2002-08-23 2006-02-23 Dainippon Sumitomo Pharma Co Ltd プロリン誘導体
US7589216B2 (en) 2002-09-19 2009-09-15 Novartis Ag Process for preparing N-hydroxyformamido-propyl pyrrolidin compounds and intermediates
JP2006519786A (ja) 2003-02-21 2006-08-31 ノバルティス アクチエンゲゼルシャフト N−ホルミルヒドロキシルアミン化合物を得るための中間体作成に関する化学的方法
TW200427458A (en) 2003-04-02 2004-12-16 Novartis Ag Crystalline N-formyl hydroxylamine compounds
CA2530142A1 (en) 2003-06-26 2005-01-06 Novartis Ag Process for preparing intermediates useful to prepare certain antibacterial n-formyl hydroxylamines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115417A (en) * 1975-10-16 1978-09-19 Hoffmann-La Roche Inc. Asymmetric hydrogenation catalyzed by rhodium complexes of chiral tertiary phosphines
US4384139A (en) * 1980-08-20 1983-05-17 Kanegafuchi Chemical Industry Company, Limited Process for preparation of an optically active β-mercaptoalkanoic acid
EP0354529A2 (en) * 1988-08-09 1990-02-14 Genencor International, Inc. Chiral hydroxycarboxylic acids from prochiral diols
WO1999039704A1 (en) * 1998-02-07 1999-08-12 British Biotech Pharmaceuticals Limited Antibacterial agents
WO2002070541A2 (en) * 2001-03-01 2002-09-12 Smith Kline Beecham Corporation Peptide deformylase inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DETLEF GEFFKEN ET AL: "Darstellung von Derivaten der 3-Hydroxypropiohydroxamsäure unter Anwendung der Carbodiimid-Methode", CHEMISCHE BERICHTE, vol. 106, 1973, pages 2246 - 2254, XP008026435 *
GRAF VON ROEDERN E ET AL: "DESIGN AND SYNTHESIS OF MALONIC ACID-BASED INHIBITORS OF HUMAN NEUTROPHIL COLLAGENASE (MMP8)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 3, 1998, pages 339 - 345, XP000919359, ISSN: 0022-2623 *
JIN Y ET AL: "Inhibition stereochemistry of hydroxamate inhibitors for thermolysin", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 24, 15 December 1998 (1998-12-15), pages 3515 - 3518, XP004150359, ISSN: 0960-894X *
JUN-ICHI SAKAKI ET AL: "Synthesis of 1,3-Dioxin-4-ones and Their Use in Synthesis. XVIII. Synthesis of Azetidin-2-ones from 1,3-Dioxin-4-ones via 3-Hydroxycarboxamides", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 37, no. 11, 1989, pages 2952 - 2960, XP002266977 *
MARVIN J. MILLER ET AL: "Synthesis of beta-Lactams from Substituted Hydroxamic Acids", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 102, no. 23, 1980, pages 7026 - 7032, XP002266979 *
MICHAEL H. RABINOWITZ ET AL: "Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor-alpha Converting Enzyme (TACE)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 2001, pages 4252 - 4267, XP002266978 *
PFEFFER, PHILIP E. ET AL: ".alpha. Anions of carboxylic acids. V. Simple high yield preparation of.alpha.-alkylhydracrylic acids and.alpha.-alkylacrylic acids", JOURNAL OF ORGANIC CHEMISTRY (1972), 37(8), 1256-8, XP002266981 *
RAMASWAMI, SURYAKUMARI ET AL: "Terpenoids. IL. The Prins reaction on the isopropylidene-type double bonds", JOURNAL OF ORGANIC CHEMISTRY (1964), 29(8), 2245-8, XP002266980 *
YONGHAO JIN ET AL: "A Practical Method for the Conversion of beta-Hydroxy Carboxylic Acids into the Corresponding beta-Amino Acids", SYNLETT, vol. 11, 1998, pages 1189 - 1190, XP008026436 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589216B2 (en) 2002-09-19 2009-09-15 Novartis Ag Process for preparing N-hydroxyformamido-propyl pyrrolidin compounds and intermediates

Also Published As

Publication number Publication date
ATE417826T1 (de) 2009-01-15
PL374961A1 (en) 2005-11-14
DE60325390D1 (de) 2009-01-29
JP2006503053A (ja) 2006-01-26
KR20050057429A (ko) 2005-06-16
ES2321504T3 (es) 2009-06-08
CN1684945A (zh) 2005-10-19
US7589216B2 (en) 2009-09-15
MXPA05003089A (es) 2005-05-27
EP1542968B1 (en) 2008-12-17
CN100439334C (zh) 2008-12-03
NO20051867D0 (no) 2005-04-18
HK1079513A1 (en) 2006-04-07
CA2499426A1 (en) 2004-04-01
RU2005111600A (ru) 2006-10-27
AU2003273404A1 (en) 2004-04-08
RU2374227C2 (ru) 2009-11-27
BR0314592A (pt) 2005-08-09
ECSP055692A (es) 2005-07-06
DK1542968T3 (da) 2009-04-20
NO20051867L (no) 2005-04-18
US20050261504A1 (en) 2005-11-24
AU2003273404B2 (en) 2008-05-22
EP1542968A1 (en) 2005-06-22
PT1542968E (pt) 2009-03-25
NZ538833A (en) 2008-05-30

Similar Documents

Publication Publication Date Title
HU196949B (en) Process for production of hydroxame-acid-derivatives and medical compositions containing them
US20090131707A1 (en) Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds
EP1542968B1 (en) Process for preparing intermediates
US20090118515A1 (en) Process for preparing intermediates useful to prepare certain antibacterial n-formyl hydroxylamines
KR960001913B1 (ko) 3-시아노-4-아릴-피롤의 제조방법
EP0156655A2 (en) Process for the preparation of pyrrolidone derivatives
WO1995017408A1 (en) Synthesis of diaryl methanes
HK1079513B (en) Process for preparing intermediates
KR960002371B1 (ko) 1-프로파르길-2,4-디옥소이미다졸리딘의 제조중간체 및 그 제조방법
ZA200501923B (en) Process for preparing intermediates.
SK20192000A3 (sk) Soli n-terc-butylhydroxylamínu
WO2001060785A1 (en) Acetal hydroxylamine compounds
US9346744B2 (en) Process for the preparation of lacosamide and its novel intermediate
EP0286279A1 (en) Synthesis of substituted pyrazoles
KR100774728B1 (ko) 펩티드 데포르밀라제 저해제로서 신규의 엔-포르밀히드록실아민 유도체 및 그 제조방법
GB2100264A (en) Process for the preparation of D-alanine and derivatives thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005/01923

Country of ref document: ZA

Ref document number: 2003273404

Country of ref document: AU

Ref document number: 200501923

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 346/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 167393

Country of ref document: IL

Ref document number: 2003755559

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 538833

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2499426

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/003089

Country of ref document: MX

Ref document number: 1020057004645

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 374961

Country of ref document: PL

Ref document number: 20038224712

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004537129

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2005111600

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 05036951

Country of ref document: CO

Ref document number: 1200500493

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 10527628

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020057004645

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003755559

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500510

Country of ref document: PH